FIG. 1.

Effect of SMAD2/3 inhibition in the presence of FSH/EGF during IVM on pregnancy outcomes. Day 4.5 blastocysts developed from COCs matured in the DMSO (0.04% [v/v]) control or with 4 μM SB-431542 in the presence of FSH (50 mIU) and EGF (10 ng/ml) were transferred to pseudopregnant recipients and outcomes were analyzed on Day 18 of pregnancy. Black and white bars represent embryos derived from oocytes matured with the DMSO carrier control and SB-431542 treatment, respectively. Data represent percentage of mean number of implantation sites (A) or fetuses (B) per embryo transferred ± SEM of seven replicate experiments. *Significant difference with P < 0.05. N = 42 embryos transferred per treatment.